Regeneron Pre-Announces $102M IPR&D Charge for Q1 2026, Impacting EPS by $0.81
REGN sits 59% above its 52-week low of $476.487.
Summary
Regeneron Pharmaceuticals expects to record a $102 million pre-tax IPR&D charge in Q1 2026, which will reduce diluted EPS by approximately $0.81.
Key Events · Earnings and Guidance · REGN
-
Pre-Announces Q1 IPR&D Charge
Regeneron Pharmaceuticals expects to include an acquired in-process research and development (IPR&D) charge of approximately $102 million on a pre-tax basis in its first quarter 2026 financial results.
-
Expected EPS Impact
The IPR&D charge is anticipated to negatively impact both GAAP and non-GAAP net income per diluted share for Q1 2026 by approximately $0.81.
-
Charge Originates from Collaborations
The charge primarily relates to premiums on equity securities purchased, as well as development milestone and up-front payments connected to collaboration and licensing agreements.
-
Preliminary Financial Estimates
The company noted that these results are preliminary, unaudited, and subject to finalization during its financial statement closing procedures.
Analysis · REGN · Life Sciences
Regeneron Pharmaceuticals has pre-announced an approximate $102 million pre-tax acquired in-process research and development (IPR&D) charge for the first quarter of 2026. This charge is expected to negatively impact both GAAP and non-GAAP net income per diluted share by approximately $0.81. While the charge is notable, it stems from collaboration and licensing agreements, which often involve upfront payments or equity premiums for future growth opportunities. Investors should factor this into their Q1 earnings expectations, noting that these are preliminary estimates.
How filings like this one have moved
In the 30 days to Oct 1, 2026, 30.2% of the 1644 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.49%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, REGN was trading at $759.62 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $80.4B. The 52-week trading range was $476.49 to $821.11. This filing was assessed with negative market sentiment and an importance score of 7 out of 10.